Curated News
By: NewsRamp Editorial Staff
December 22, 2025
DiNAQOR Bolsters Leadership with Key Appointments to Scale Biotech Ventures
TLDR
- DiNAQOR AG appoints Dr. Christian Thirion as CEO of DiNATEQ AG and Group Chief Strategy Officer, leveraging his proven track record to accelerate partnerships and commercial success in advanced therapies.
- DiNAQOR AG strengthens its leadership with Dr. Christian Thirion overseeing strategy and Dr. Josef El Andari as CSO, focusing on translating closed-loop perfusion technology into clinical applications.
- These appointments at DiNAQOR AG aim to advance precision delivery technologies for genetic therapies, potentially improving treatments for organ-specific diseases and addressing unmet medical needs.
- Dr. Christian Thirion, who built Sirion Biotech into a global leader before its acquisition, now leads DiNATEQ AG's innovative closed-loop perfusion platform for therapeutic delivery.
Impact - Why it Matters
This leadership restructuring matters because it positions DiNAQOR to accelerate the development of precision delivery technologies for genetic and advanced therapies, potentially transforming treatment for organ-specific diseases. With Dr. Thirion's proven track record in building successful biotech companies and forging pharmaceutical partnerships, and Dr. El Andari's deep scientific expertise in genomic medicine and viral vectors, DiNAQOR strengthens its ability to translate innovative science into clinically relevant therapies. For patients, this could mean faster access to safer, more effective treatments for conditions that currently lack good options. For the biotech industry, it demonstrates a model for successfully scaling early-stage innovations through strategic company-building and partnerships.
Summary
In a strategic move to bolster its position as a life science company builder, DiNAQOR AG has announced key leadership appointments that signal its commitment to scaling next-generation biotechnology ventures. The Swiss-based health technology group has appointed seasoned biotech entrepreneur Dr. Christian Thirion as CEO of its spin-out DiNATEQ AG, which focuses on the clinical translation of the closed-loop loco-regional perfusion (LRP) delivery platform. Simultaneously, Dr. Thirion assumes the newly created role of Group Chief Strategy and Business Development Officer at DiNAQOR AG, where he will lead corporate strategy, strategic partnerships, and M&A activities. Dr. Thirion brings over two decades of entrepreneurial experience, most notably as founder and former CEO of Sirion Biotech, which he built into a global market leader in viral vector engineering and AAV-based gene delivery before its acquisition by PerkinElmer.
In parallel, DiNAQOR has promoted Dr. Josef El Andari to Chief Scientific Officer of DiNAQOR AG. Dr. El Andari, who has been with the company for more than four years, played a central role in advancing the company's scientific platforms, including developing the closed-loop perfusion technology from concept to publication in leading peer-reviewed journals. His expertise spans genomic medicine, translational research, and advanced viral vector technologies, particularly AAV design and bioengineering. These appointments strengthen DiNAQOR's integrated approach to turning scientific innovation into impactful biotechnology companies, with a focus on precision delivery technologies for genetic and advanced therapies.
DiNAQOR operates as a life science company builder, creating and scaling focused biotechnology companies around differentiated technology platforms. The company has demonstrated its value-creation capabilities through strategic transactions, including the recent M&A of DiNAMIQS, a specialized adeno-associated virus (AAV) manufacturing and development company. For more information, visit www.dinaqor.com, and view the original release on www.newmediawire.com. These leadership changes come as DiNAQOR continues to build an exceptional ecosystem for translating breakthrough technologies into clinical and commercial success, addressing significant unmet medical needs through innovative delivery platforms and strategic pharmaceutical partnerships.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, DiNAQOR Bolsters Leadership with Key Appointments to Scale Biotech Ventures
